<DOC>
	<DOC>NCT00557505</DOC>
	<brief_summary>P-cadherin may play a part in tumor growth; PF-03732010 is a new drug that inhibits P-cadherin. This study will test how well the drug is tolerated, and what effects there might be. Blood will also be taken to measure the amount of drug in blood.</brief_summary>
	<brief_title>A Study Of PF-03732010 In Patients With Advanced Solid Tumors</brief_title>
	<detailed_description />
	<criteria>Advanced solid tumors refractory to (or intolerant of) established therapy known to provide clinical benefit, or for which there is no standard therapy Age &gt;= 18 years of age Adequate bone marrow function as defined by: absolute neutrophil count (ANC) ≥1500/uL, hemoglobin ≥ 9 g/dL, platelets &gt; 100,000/uL Adequate liver function as defined by: bilirubin &lt; 1.5 x ULN, AST, ALT and ALP &lt; 2.5 x ULN, or &lt; 5 x ULN with documented liver and/or bone metastases Serum creatinine &lt; 1.5 x ULN ECOG status 01 Availability of biopsy tumor tissue (or fine needle aspirate) for testing of Pcadherin expression Tumor tissue (or fine needle aspirate) showing overexpression of Pcadherin Must be able to give written informed consent Be able to comply with scheduled study visits, treatment plans, laboratory tests and other procedures Chemotherapy, radiotherapy, or any investigational cancer therapy within 4 weeks of study entry Patients with carcinomatous meningitis or untreated brain metastases. History of significant low platelet count, and/or bleeding disorders, requiring medical or surgical intervention History of significant bleeding episodes within 6 months, unless the source of bleeding has been resected</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2012</verification_date>
</DOC>